We are live on ! Find out more
STSA

Satsuma Pharmaceuticals, Inc. Common Stock

Delisted

STSA was delisted on the 7th of June, 2023.

35 hedge funds and large institutions have $104M invested in Satsuma Pharmaceuticals, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 9 increasing their positions, 11 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

4% less capital invested

Capital invested by funds: $108M → $104M (-$4.62M)

18% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 11

22% less funds holding

Funds holding: 4535 (-10)

67% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 12

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $1K

Holders
35
Holders Change
-10
Holders Change %
-22.22%
% of All Funds
0.54%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
4
Increased
9
Reduced
11
Closed
12
Calls
Puts
$1K
Net Calls
-$1K
Net Calls Change
+$171K

STSA Hedge Fund Activity: Q4 2021 in Review

35 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Satsuma Pharmaceuticals, Inc. Common Stock (STSA) for Q4 2021, worth a combined $104M — down 4.3% from $108M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of STSA and 4 opened new positions — a net loss of 8 holders — while 11 trimmed existing stakes and 9 added.

The largest buyer was Commodore Capital, adding an estimated $3.01M. The largest seller was Healthcare of Ontario Pension Plan (HOOPP) Trust Fund, cutting an estimated $805K.

  • 35 institutional investors held Satsuma Pharmaceuticals, Inc. Common Stock (STSA) as of Q4 2021, down from 45 in Q3 2021.
  • Funds reported $104M of Satsuma Pharmaceuticals, Inc. Common Stock stock for Q4 2021, down 4.3% quarter-over-quarter.
  • 4 funds opened new Satsuma Pharmaceuticals, Inc. Common Stock positions in Q4 2021 and 12 closed out, a net change of -8 holders.
  • The largest Satsuma Pharmaceuticals, Inc. Common Stock buyer in Q4 2021 was Commodore Capital, an estimated $3.01M added.
  • The largest Satsuma Pharmaceuticals, Inc. Common Stock seller in Q4 2021 was Healthcare of Ontario Pension Plan (HOOPP) Trust Fund, an estimated $805K sold.

Based on aggregated 13F filings for Q4 2021.